Update Note: This article reports new post-hoc findings from the ATTAIN-1 trial of Foundayo (orforglipron), released by Eli Lilly on October 1, 2026, and published in the journal Diabetes, Obesity and Metabolism, following MedicalDaily's earlier coverage of the drug's approval and diabetes trials.
Adults with obesity or overweight who took the highest dose of Eli Lilly's once-daily weight loss pill Foundayo had a 57% lower predicted 10-year risk of developing type 2 diabetes than those on placebo, according to new analyses of the ATTAIN-1 trial. The figure comes from a risk calculator, not from counting people who actually developed diabetes. Lilly sponsored the trial and announced the results.
